Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia

Annals of the New York Academy of Sciences

Volumn 1003, Issue , 2003, Pages 318-327

  Coyle, Joseph T ^a,c   Tsai, Guochuan ^a,c   Goff, Donald ^b,c  

^a MCLEAN HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

D cycloserine; D serine; Glycine; Glycine modulatory site; GlyT1; Negative symptoms; NMDA receptor; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; CYCLOSERINE; GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PLACEBO; SARCOSINE; SERINE DERIVATIVE;

AGONIST; AMINO ACID BLOOD LEVEL; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; DOPAMINE RELEASE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; EXTRAPYRAMIDAL SYMPTOM; GABAERGIC TRANSMISSION; GENETIC LINKAGE; GENETIC RISK; HUMAN; NEGATIVE SYNDROME; NEUROPATHOLOGY; POSITIVE SYNDROME; RECEPTOR INTRINSIC ACTIVITY;

EID: 0347091918     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1300.020     Document Type: Conference Paper

References (53)

1. GOFF, D. & J.T. COYLE. 2001. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry 158(9): 1367-1377.
2. HARRISON, P.J. & M.J. OWEN. 2003. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 361(9355): 417-419.
3. TSUANG, M. 2000. Schizophrenia: genes and environment. Biol. Psychiatry 47(3): 210-220.
4. SNYDER, S.H. 1981. Dopamine receptors, neuroleptics, and schizophrenia. Am. J. Psychiatry 138(4): 460-464.
5. MELTZER, H.Y. 1997. Treatment-resistant schizophrenia - the role of clozapine. Curr Med. Res. Opin. 14(1): 1-20.
6. ITIL, T. et al. 1967. Effect of phencyclidine in chronic schizophrenics. Can. Psychiatr. Assoc. J. 12(2): 209-212.
7. LUBY, E.D. et al. 1959. Study of a new schizophrenomimetic drug - sernyl. Arch. Neurol. Psychiatry 81: 363-369.
8. JAVITT, D.C. & S.R. ZUKIN. 1991. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148(10): 1301-1308.
9. KRYSTAL, J.H. et al. 1994. Subanaesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51(3): 199-214.
10. MALHOTRA, A.K. et al. 1997. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17(3): 141-150.
11. NEWCOMER, J. et al. 1999. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20(2): 106-118.
12. UMBRICHT, D. et al. 2002. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol. Psychiatry 51(5): 400-406.
13. AVILA, M.T. et al. 2002. Effects of ketamine on leading saccades during smooth-pursuit eye movements may implicate cerebellar dysfunction in schizophrenia. Am. J. Psychiatry 159(9): 1490-1496.
14. 18F] fluorodeoxyglucose (FDG). Eur. Neuropsychopharmacol. 7(1): 9-24.
15. MOGHADDAM, B. et al. 1997. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17(8): 2921-2927.
16. KEGELES, L.S. et al. 2000. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Proc. Natl. Acad. Sci. USA 48(7): 627-640.
17. TSIEN, J.Z. 2000. Linking Hebb's coincidence-detection to memory formation. Curr. Opin. Neurobiol. 10(2): 266-273.
18. MOTHET, J.-P. et al. 2000. D-Serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc. Natl. Acad. Sci. USA 97(9): 4926-4931.
19. KIM, K.M. et al. 1994. Cloning of the human glycine transporter type 1: molecular and pharmacological characterization of novel isoform variants and chromosomal localization of the gene in the human and mouse genomes. Mol. Pharmacol. 45(4): 608-617.
20. BERGERON, R. et al. 1998. Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc. Natl. Acad. Sci. USA 95(26): 15730-15734.
21. BERGER, A.J. et al. 1998. Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses. J. Neurophysiol. 80(6): 3336-3340.
22. CHEN, L. et al. 2003. Glycine transporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J. Neurophysiol. 89(2): 691-703.
23. SCHWARCZ, R. et al. 2001. Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry 50(7): 521-530.
24. BERGER, U.V. et al. 1999. Glutamate carboxypeptidase II is expressed by astrocytes in the rat nervous system. J. Comp. Neurol. 415: 52-64.
25. TSAI, G. et al. 1995. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry 52(10): 829-836.
26. HAKAK, Y. et al. 2001. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl. Acad. Sci. USA 98(8): 4746-4751.
27. LEA, P.M. IV et al. 2001 beta-NAAG rescues LTP from blockade by NAAG in rat dentate gyrus via the type 3 metabotropic glutamate receptor. J. Neurophysiol. 85(3): 1097-1106.
28. MARTI, S.B. et al. 2002. Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population. Am. J. Med. Genet. 114(1): 46-50.
29. CHUMAKOV, I. et al. 2002 Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc. Natl. Acad. Sci. USA 99(21): 13675-13680.
30. HASHIMOTO, K. et al. 2003. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry 60(6): 572-576.
31. BUONANNO, A. et al. 2001 Receptor signaling pathways in the nervous system. Curr. Opin. Neurobiol. 11(3): 287-296.
32. STEFANSSON, H. et al. 2002. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71(4): 877-892.
33. COYLE, J.T. 1996. The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Rev. Psychiatry 3(5): 241-253.
34. GRUNZE, H.C. et al. 1996. NMDA-dependent modulation of CA1 local circuit inhibition. J. Neurosci. 16(6): 2034-2043.
35. FARBER, N.B. et al. 1995. Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia? Biol. Psychiatry 15: 788-796.
36. LI, Q. et al. 2002. NMDA receptor antagonists disinhibit rat posterior cingulate and retrosplenial cortices: a potential mechanism of neurotoxicity. J. Neurosci. 22: 3070-3080.
37. GUIDOTTI, A. et al. 2000. Decrease in reelin and glutamic acid decarboxylase67 (GAD 67) expression in schizophrenia and bipolar disorder: A postmortem study. Arch. Gen Psychiatry 57(11): 1061-1069.
38. VOLK, D. et al. 2000. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch. Gen Psychiatry 57: 237-245.
39. VOLK, D. et al. 2001. GABA transporter-1 mRNA in prefrontal cortex in schizophrenia: decreased expression in a subset of neurons. Am. J. Psychiatry 158(2): 256-265.
40. VOLK, D.W. et al. 2002. Reciprocal alterations in pre-and post-synaptic inhibitory markers at chandler cell inputs to pyramidal neurons in schizophrenia. Cereb. Cortex 12(10): 1063-1070.
41. BENES, F.M. et al. 1996. Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience 75(4): 1021-1031.
42. PAULSON, L. et al. 2003. Comparative genome-and proteome analysis of cerebral cortex from MK-801-treated rats. J. Neurosci. Res. 71(4): 526-533.
43. COYLE, J.T. et al. 2002. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr. Drug Targets CNS Neurol. Disorders 1: 183-189.
44. JAVITT, D.C. et al. 1999. AE Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biol. Psychiatry 45(6): 668-679.
45. HERESCO-LEVY, U. et al. 1999. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry 56(1): 29-36.
46. TSAI, G. et al. 1998. D-Serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 44(11): 1081-1089.
47. SHEININ, A. et al. 2001. Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine. Neuropharmacology 41(2): 151-158.
48. COOK, S.P. et al. 2002. Direct calcium binding results in activation of brain serine racemase. J. Biol. Chem. 277: 27782-27792.
49. GOFF, D.C, et al. 1995. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am. J. Psychiatry 152(8): 1213-1215.
50. GOFF, D.C. et al. 1999. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psychiatry 56(1): 21-27.
51. HORESCO-LEVY, U. et al. 2002. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am. J. Psychiatry 159: 480-482.
52. TSAI, G. et al. 2003. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for treatment of schizophrenia. Biol. Psychiatry. In press.
53. KASAI, K. et al. 2003. Progressive decrease of left Heschl gyrus and planum temporale gray matter volume in first-episode schizophrenia: a longitudinal magnetic resonance imaging study. Arch. Gen. Psychiatry 60(8): 766-775.